Lifestyle Management in T1D

Video

Tina Q Tan, MD, and Kimberly Simmons, MD, discuss lifestyle changes such as a balanced diet and glucose monitoring in the management of pediatric T1D.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      Greg Forlenza, MD
      Greg Forlenza, MD, discusses CLVer trial among newly diagnosed type 1 diabetes patients
      Greg Forlenza, MD
      Screening for diabetes in primary care and CGM, AID advice for providers
      Greg Forlenza, MD
      Keeping up with type 1 diabetes technology changes in primary care
      Herbert Bravo, MD
      Autoimmune diabetes and preventing diabetic ketoacidosis
      Brittany Bruggeman, MD
      New glucagon formulations simplify emergency treatment for T1D patients
      Brittany Bruggeman, MD
      Communicating availability of continuous glucose monitors for type 1 diabetes patients
      Brittany Bruggeman, MD
      Testing for islet autoantibodies to monitor type 1 diabetes development
      3 KOLs are featured in this series.
      Central Precocious Puberty in Male Patients
      3 KOLs are featured in this series.
      Recommendations and Outlook for Central Precocious Puberty
      3 KOLs are featured in this series.
      Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions
      Related Content
      Diabetes device data may fail to deliver based on smartphone settings | Image Credit: © KRISTINA KUPTSEVICH - © KRISTINA KUPTSEVICH - stock.adobe.com.

      Diabetes device data may fail to deliver based on smartphone settings

      Joshua Fitch, Senior Editor
      February 5th 2025
      Article

      The FDA is warning diabetes patients that information from CGMs, insulin pumps, and automated dosing systems could fail to be delivered if smartphone settings are not properly configured.

      Image Credit: © Calin - stock.adobe.com

      FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

      Patrick Campbell
      December 23rd 2024
      Article

      The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

      Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial | Image Credit: © Africa Studio - © Africa Studio - stock.adobe.com.

      Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

      Joshua Fitch, Senior Editor
      December 20th 2024
      Article

      The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

      Resilience programs improve behavioral outcomes in adolescents with T1D distress | Image Credit: © Alina - © Alina - stock.adobe.com.

      Resilience programs improve behavioral outcomes in adolescents with T1D distress

      Joshua Fitch, Senior Editor
      October 16th 2024
      Article

      Investigators sought to test the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention on levels of HbA1c.

      Image Credit: © Artur - ©Artur - stock.adobe.com.

      Weekly review: Extended labels, T1D inheritance data, and more

      Joshua Fitch, Senior Editor
      August 2nd 2024
      Article

      Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

      Phase 3 type 1 diabetes precision medicine trial receives positive interim analysis | Image Credit: © Michael O'Neill - © Michael O'Neill - stock.adobe.com.

      Diamyd phase 3 type 1 diabetes precision medicine trial receives positive interim analysis

      Joshua Fitch, Senior Editor
      August 1st 2024
      Article

      Diamyd to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.

      © 2025 MJH Life Sciences

      All rights reserved.